Jin Dick Vice President, personal reasons resignation request

On March 21, 2026, Jindike announced that due to personal reasons, Mr. Zou Jingyu will no longer serve as Deputy General Manager and will resign from all company positions.

According to information, Mr. Zou Jingyu, born in December 1976, is a Chinese national with no permanent residence abroad. He holds a bachelor’s degree, is a licensed pharmacist, and a senior engineer. From September 2000 to March 2002, he worked as a fermentation and extraction researcher and head of the solid oral dosage form department at Wuxi Second Pharmaceutical Factory’s Product Development Research Institute; from March 2002 to March 2003, he served as Assistant Director of the Science and Technology Cooperation Department at the Shanghai Branch of the Chinese Academy of Sciences; from March 2003 to November 2004, he was Deputy Director of the Product Development Research Institute at Wuxi Second Pharmaceutical Factory; from November 2004 to July 2007, he served successively as Technical Director of Antibiotic Workshop 1 and Director of Synthesis Workshop 3 at Wuxi Second Pharmaceutical Factory; from July 2007 to May 2020, he held positions including Production Technology Manager, Production Director and Production Technology Manager, Quality Director, Quality Responsible Person, and Quality Authorized Person at Wuxi Fuki Pharmaceutical Co., Ltd.; from May 2020 to January 2021, he was CMO Director at Zhuohe Pharmaceutical Group Co., Ltd.; from February 2021 to May 2024, he was Head of Quality at Luoyi (Wuxi) Biopharmaceutical Co., Ltd.

In June 2024, Xia Luhua, Vice General Manager of Quality at Jindike, resigned less than half a year after taking office, and Mr. Zou Jingyu was officially announced to have joined and succeeded in this position.

Jindike’s 2024 annual report shows that among 13 directors and senior managers, General Manager Zhang Jianhui received the highest salary of 1.739 million yuan, while Mr. Zou Jingyu’s pre-tax annual salary in 2024 was 834,300 yuan.

It is reported that during his tenure at Jindike, Mr. Zou Jingyu participated in the promotion of several key projects, making significant contributions to the company’s development.

Jindike Biotech Co., Ltd. was established in 2008 and listed on the STAR Market in 2021. It is one of the few domestic biopharmaceutical companies with both large-scale production capacity for influenza vaccines and a diverse vaccine R&D pipeline. The company is headquartered in Nantong, Jiangsu, and has a GMP-compliant vaccine production base. Its core business covers the entire chain of R&D, production, and sales of human vaccines, mainly for the prevention of influenza, rabies, and other common infectious diseases.

On February 12, 2026, Jindike released its 2025 performance brief. During the reporting period, the company achieved operating revenue of 113 million yuan, up 40.13% from 80.08 million yuan in the same period last year; net profit attributable to the parent was -173 million yuan, compared to -93.5 million yuan in the same period last year, with the loss widening.

All specific information is subject to the company’s official statement.